7 research outputs found
Characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.
<p>Characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.</p
Flow chart of article selection (PRISMA flow diagram).
<p>Flow chart of article selection (PRISMA flow diagram).</p
Characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.
<p>Characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.</p
Risk of cardiovascular events between patients with type 2 diabetes mellitus with no other complications treated with incretin or control.
<p>Risk of cardiovascular events between patients with type 2 diabetes mellitus with no other complications treated with incretin or control.</p
Intervention characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.
<p>Intervention characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.</p
Subgroup analysis by types of incretin therapy.
<p>Subgroup analysis by types of incretin therapy.</p
DataSheet1_Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia.PDF
Background: Everolimus is an inhibitor of mammalian target of rapamycin complex 1. As mutations in TSC1 and TSC2, which cause partial-onset seizures associated with TSC, were found in focal cortical dysplasia type Ⅱ (FCD Ⅱ) patients, a clinical trial has been performed to explore the efficacy and safety of everolimus in FCD patients. However, no dosage regimen was determined to treat FCD II. To recommend an optimal dose regimen for FCD patients, a population pharmacokinetic model of everolimus in FCD patients was developed.Methods: The data of everolimus were collected from September 2017 to May 2020 in a tertiary-level hospital in Korea. The model was developed using NONMEM® software version 7.4.1 (Icon Development Solutions, Ellicott City, MD, United States).Results: The population pharmacokinetics of everolimus was described as the one-compartment model with first-order absorption, with the effect of BSA on clearance. The final model was built as follows: TVCL = 12.5 + 9.71 × (BSA/1.5), TVV = 293, and TVKA = 0.585. As a result of simulation, a dose higher than 7 mg/m2 is needed in patients with BSA 0.5 m2, and a dose higher than 6 mg/m2 is needed in patients with BSA 0.7 m2. A dose of 4.5 mg/m2 is enough in the population with BSA higher than 1.5 m2 to meet the target trough range of 5–15 ng/mL.Conclusion: Based on the developed pharmacokinetics model, the optimal dose of everolimus in practice was recommended by considering the available strengths of Afinitor disperz®, 2 mg, 3 mg, and 5 mg.</p